Table 2.
Association of PSIP1 SNPs with HIV-1 acquisition in the CAPRISA AI 002 cohort, dominant model
| SNP Risk group | n | Genotype |
22 and 12 versus 11 (reference group)* |
|||
|---|---|---|---|---|---|---|
| Number (Frequency) | RH (95% CI) | P - value | ||||
| SNP1 | GG | AG | AA | |||
| G→A | ||||||
| SN | 183 | 158 (0.86) | 22 (0.12) | 3 (0.02) | ||
| SP | 52 | 39 (0.75) | 12 (0.23) | 1 (0.01) | 2.21 (0.92 – 5.28) | 0.08 |
| SNP2 | GG | CG | CC | |||
| G→C | ||||||
| SN | 181 | 66 (0.36) | 77 (0.43) | 38 (0.21) | ||
| SP | 52 | 20 (0.38) | 23 (0.44) | 9 (0.17) | 0.99 (0.44 – 2.24) | 0.98 |
| SNP3 | TT | CT | CC | |||
| T→C | ||||||
| SN | 172 | 86 (0.49) | 64 (0.36) | 22 (0.13) | ||
| SP | 50 | 29 (0.58) | 19 (0.38) | 2 (0.04) | 0.60 (0.26 – 1.37) | 0.23 |
| SNP4 | AA | AG | GG | |||
| A→G | ||||||
| SN | 172 | 108 (0.63) | 53 (0.31) | 11 (0.06) | ||
| SP | 48 | 31 (0.65) | 16 (0.33) | 1 (0.02) | 0.85 (0.36 – 2.01) | 0.71 |
| SNP5 | AA | AT | TT | |||
| A→T | ||||||
| SN | 184 | 162 (0.88) | 21 (0.11) | 1 (0.005) | ||
| SP | 51 | 41 (0.80) | 10 (0.20) | 0 (0.00) | 1.90 (0.71 – 5.09) | 0.20 |
Kaplan-Meier survival statistics and the Cox proportional hazards model (Cox model) were used to assess the effect of each SNP on time to HIV-1 acquisition after enrollment.
P-values uncorrected for multiple comparisons are shown.